• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Paragon 28 Inc.

    2/9/22 9:05:47 AM ET
    $FNA
    Medical/Dental Instruments
    Health Care
    Get the next $FNA alert in real time by email
    SC 13G 1 mvmsc13g.htm MVM PARTNERS LP FORM SC 13G

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No.  )


    Paragon 28, Inc.

    (Name of Issuer)

    Common Stock, $0.01 par value per share
    (Title of Class of Securities)

    69913P105
    (CUSIP Number)

     

    October 18, 2021
    (Date of Event Which Requires Filing of This Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    o Rule 13d-1(b)

    o Rule 13d-1(c)

    x Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     
    CUSIP No. 69913P105SCHEDULE 13G

     

    1

    NAMES OF REPORTING PERSONS OR

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

    MVM Partners LP

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) o
    (b) o

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United Kingdom

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER (1)

     

    14,414,195

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    14,414,195

    8

    SHARED DISPOSITIVE POWER

     

    0


    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    14,414,195

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    o

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    18.9% (1)

    12

    TYPE OF REPORTING PERSON

     

    PN

     

     

    (1) All share numbers reported herein are as of October 18, 2021, unless otherwise indicated.

    (2) All ownership percentages reported herein are based on 76,374,880 outstanding shares of the Issuer’s common stock as of November 19, 2021, based on the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 22, 2021.

     

     
    CUSIP No. 69913P105SCHEDULE 13G

     

     

    1

    NAMES OF REPORTING PERSONS OR

    I.R.S. INDENTIFICATION NO. OF ABOVE PERSON

     

    MVM V LP

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a) o
    (b) o

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United Kingdom

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    –

    6

    SHARED VOTING POWER (1)

     

    5,620,050

    7

    SOLE DISPOSITIVE POWER

     

    –

    8

    SHARED DISPOSITIVE POWER

     

    5,620,050


    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    5,620,050

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    o

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    7.4% (1)

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    PN

     

     

    (1) All share numbers reported herein are as of October 18, 2021, unless otherwise indicated.

    (2) All ownership percentages reported herein are based on 76,374,880 outstanding shares of the Issuer’s common stock as of November 19, 2021, based on the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 22, 2021.

     
    CUSIP No. 69913P105SCHEDULE 13G

     

     

     

    1

    NAMES OF REPORTING PERSONS OR

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

    MVM V (2020) LP

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a) o
    (b) o

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United Kingdom

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    –

    6

    SHARED VOTING POWER (1)

     

    8,709,825

    7

    SOLE DISPOSITIVE POWER

     

    –

    8

    SHARED DISPOSITIVE POWER

     

    8,709,825


    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    8,709,825

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    o

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    11.4% (1)

    12

    TYPE OF REPORTING PERSON

     

    PN

     

     

     

    (1) All share numbers reported herein are as of October 18, 2021, unless otherwise indicated.

    (2) All ownership percentages reported herein are based on 76,374,880 outstanding shares of the Issuer’s common stock as of November 19, 2021, based on the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 22, 2021.

     

     
    CUSIP No. 69913P105SCHEDULE 13G

     

     

     

    1

    NAMES OF REPORTING PERSONS OR

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

    MVM GP (No. 5) LP

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a) o
    (b) o

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United Kingdom

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    –

    6

    SHARED VOTING POWER (1)

     

    84,320

    7

    SOLE DISPOSITIVE POWER

     

    –

    8

    SHARED DISPOSITIVE POWER

     

    84,320


    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    84,320

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    o

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.1% (1)

    12

    TYPE OF REPORTING PERSON

     

    PN

     

     

     

    (1) All share numbers reported herein are as of October 18, 2021, unless otherwise indicated.

    (2) All ownership percentages reported herein are based on 76,374,880 outstanding shares of the Issuer’s common stock as of November 19, 2021, based on the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 22, 2021.

     

     
    CUSIP No. 69913P105SCHEDULE 13G

     

    This Schedule 13G is being filed on behalf of (i) MVM Partners LLP (“MVM Partners”), (ii) MVM V LP (“MVM V”), (iii) MVM V (2020) LP (“MVM V 2020”) and (iv) MVM GP (No. 5) LP (“MVM GP”, collectively with MVM V and MVM V 2020, the “Funds” and collectively with MVM Partners, MVM V and MVM V 2020, the “Reporting Persons”).

    with the U.S. Securities and Exchange Commission (the “Commission”) on February 8, 2022 (the “Schedule 13G”), relating to the Common Stock, $0.001 par value per share (the “Common Stock”), of Paragon 28, Inc. (the “Issuer”).

     

    MVM Partners provides investment advisory services to the Funds, which directly hold the shares of Common Stock reflected as being beneficially owned by the Funds herein, and in such capacity MVM Partners has voting and dispositive power over such shares. Investment decisions for the Funds are made by an investment committee at MVM Partners which consists of five individuals. No single individual member of the Investment Committee, or any other individual at MVM Partners, has the power to unilaterally make investment decisions for MVM Partners or the Funds or to direct the voting or disposition of the shares.

     

    The Reporting Persons have entered into a joint filing agreement, dated February 8, 2022, a copy of which is attached hereto as Exhibit 1

     

    Item 1. (a) Name of Issuer:
        Paragon 28, Inc.
         
      (b) Address of Issuer’s Principal Executive Offices:
       

     

    8310 South Valley Highway

    Suite 3115

    Englewood, CO 80112

       
    Item 2. (a) - (c) Name of Person Filing; Address of Principal Business Office; and Citizenship
       

     

    MVM Partners LLP, MVM V LP, MVM V (2020) LP and MVM GP (No. 5) LP are all entities formed under the laws of the United Kingdom.

     

    The principal business address and principal office of the Reporting Persons is 30 St. George Street, London, United Kingdom W1S SFH.

     

         
      (d) Title of Class of Securities: Common Stock
         
      (e) CUSIP Number: 69913P105

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO SS.240.13D-1(B) OR 240.13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A:
         
      (a) [__] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o)
      (b) [__] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c)
      (c) [__] Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c)
      (d) [__] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8)
      (e) [__] An investment adviser in accordance with ss.240.13d-1(b)(1)(ii)(E)
      (f) [__] An employee benefit plan or endowment fund in accordance with ss.240.13d-1(b)(1)(ii)(F);
      (g) [__] A Parent holding company or control person in accordance with ss.240.13d-1(b)(1)(ii)(G);
      (h) [__] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813)
      (i) [__] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3)
      (j) [__] Group, in accordance with ss.240.13d-1(b)(1)(ii)(J).

     

     
    CUSIP No. 69913P105SCHEDULE 13G

     

    Item 4. OWNERSHIP
       
     

    (a) Amount Beneficially Owned:

    MVM Partners. – 14,414,195

    MVM V – 5,620,050

    MVM V 2020– 8,709,825

    MVM GP – 84,320

     

     

    (b) Percent of Class:

     

    MVM Partners. – 18.9%

    MVM V – 7.4%

    MVM V 2020– 11.4%

    MVM GP – 0.1%

     

    (c) Number of Shares to which such person has:

    (i) Sole power to vote or direct the vote:

     

    MVM Partners. – 14,414,195

    MVM V – 0

    MVM V 2020– 0

    MVM GP – 0

     

    (ii) Shared power to vote or direct the vote:

     

    MVM Partners. – 0

    MVM V – 5,620,050

    MVM V 2020– 8,709,825

    MVM GP – 84,320

     

    (iii) Sole power to dispose or to direct the disposition of:

     

    MVM Partners. – 14,414,195

    MVM V – 0

    MVM V 2020– 0

    MVM GP – 0

     

    (iv) Shared power to dispose or to direct the disposition of:

     

    MVM Partners. – 0

    MVM V – 5,620,050

    MVM V 2020– 8,709,825

    MVM GP – 84,320

     

     

       

     


    Item 5.
    OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
       
     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. ☐

     

       
    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
       
      Not applicable
       
    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
       
      Not applicable.

     

     
    CUSIP No. 69913P105SCHEDULE 13G

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
       
      Each of the Reporting Persons may be deemed to be a member of a group with respect to the Issuer or securities of the Issuer for the purpose of Section 13(d) or 13(g) of the Securities Exchange Act of 1934, as amended.
       
    Item 9. NOTICE OF DISSOLUTION OF GROUP.
       
      Not applicable.
       
    Item 10. CERTIFICATIONS.
       
      By signing below the undersigned certify that, to the best of their knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing of influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     
    CUSIP No. 69913P105SCHEDULE 13G

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 8, 2022 MVM Partners LLP
       
      By: /s/ Neil Akhurst
      Name: Neil Akhurst
      Title: Partner
         
      MVM V LP
       By: MVM Partners LLP, its Fund Manager
      By: /s/ Neil Akhurst
      Name: Neil Akhurst
      Title: Partner
         
      MVM V (2020) LP
       By: MVM Partners LLP, its Fund Manager
      By: /s/ Neil Akhurst
      Name: Neil Akhurst
      Title: Partner
         
      MVM GP (No. 5) LP
       By: MVM Partners LLP, its Fund Manager
      By: /s/ Neil Akhurst
      Name: Neil Akhurst
      Title: Partner

     

    Get the next $FNA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FNA

    DatePrice TargetRatingAnalyst
    1/29/2025Buy → Hold
    Needham
    1/29/2025Outperform → Mkt Perform
    William Blair
    9/29/2023Outperform
    William Blair
    4/11/2023$23.00Overweight
    Stephens
    12/14/2022$32.00Buy
    B. Riley Securities
    3/9/2022$30.00 → $25.00Buy
    B of A Securities
    3/9/2022$25.00 → $23.00Buy
    Canaccord Genuity
    2/9/2022$31.00 → $25.00Buy
    Needham
    More analyst ratings

    $FNA
    Financials

    Live finance-specific insights

    See more
    • Zimmer Biomet Announces Fourth Quarter and Full-Year 2024 Financial Results

      Fourth quarter net sales of $2.023 billion increased 4.3% and 4.9% on a constant currency1 basisFourth quarter diluted earnings per share were $1.20; adjusted1 diluted earnings per share were $2.31Full-year net sales of $7.679 billion increased 3.8% and 4.8% on a constant currency1 basisFull-year diluted earnings per share were $4.43; adjusted1 diluted earnings per share were $8.00Company provides full-year 2025 financial guidanceWARSAW, Ind., Feb. 6, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter and year ended December 31, 2024.  The Company reported fourth quarter net sales of $2.023 billion, an increase of 4.3% over

      2/6/25 6:30:00 AM ET
      $FNA
      $ZBH
      Medical/Dental Instruments
      Health Care
      Industrial Specialties
    • Paragon 28 Reports Third Quarter 2024 Financial Results and Raises 2024 Net Revenue Guidance

      Paragon 28, Inc. (NYSE:FNA) ("Paragon 28" or "Company"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended September 30, 2024 and raised its 2024 net revenue guidance. Recent Business Updates Recorded global net revenue of $62.3 million in the third quarter, representing 18.1% and 17.6% reported and constant currency growth compared to the prior year period, respectively Raised net revenue guidance to $252 million to $256 million for full year 2024 net revenue, representing 16.5% to 18.3% reported growth compared to 2023 Drove a 969 basis point improvement in operating expense as a

      11/12/24 4:05:00 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care
    • Paragon 28 To Report Third Quarter 2024 Financial Results on November 12, 2024

      Paragon 28, Inc. (NYSE:FNA) ("PARAGON"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the third quarter 2024 after market close on Tuesday, November 12, 2024. The Company's management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time / 2:30 p.m. Mountain Time. Investors interested in listening to the conference call may do so by dialing (833-470-1428) for domestic callers or (404-975-4839) for international callers, using conference ID: 725499. Live audio of the webcast will be available on the "Investors" section of the Company's website at: ir.paragon28.com. The

      10/17/24 4:05:00 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care

    $FNA
    SEC Filings

    See more
    • SEC Form S-8 POS filed by Paragon 28 Inc.

      S-8 POS - Paragon 28, Inc. (0001531978) (Filer)

      4/21/25 4:24:46 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 POS filed by Paragon 28 Inc.

      S-8 POS - Paragon 28, Inc. (0001531978) (Filer)

      4/21/25 4:23:46 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 POS filed by Paragon 28 Inc.

      S-8 POS - Paragon 28, Inc. (0001531978) (Filer)

      4/21/25 4:22:43 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care

    $FNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Paragon 28 to Showcase Recent Product Launches at The American College of Foot and Ankle Surgeons Annual Conference

      Paragon 28, Inc. (NYSE:FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, is pleased to announce its participation in the American College of Foot and Ankle Surgeons (ACFAS) Annual Scientific Conference. From March 27-29, Paragon 28 will feature a suite of recently launched products designed to improve foot and ankle patient outcomes and surgeon experience. "We are thrilled to engage with foot and ankle specialists at ACFAS and showcase our latest innovations after an incredibly strong product launch cadence in 2024," said Albert DaCosta, CEO of Paragon 28. "Our progress and innovation in the space is a testament to our mission to continuous

      3/24/25 4:05:00 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care
    • Paragon 28 Announces Expiration of HSR Act Waiting Period for Pending Acquisition by Zimmer Biomet Under HSR Act

      Paragon 28, Inc. (NYSE:FNA) ("Paragon 28" or "Company"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act") in connection with the previously announced acquisition of Paragon 28 by Zimmer Biomet Holdings, Inc. (NYSE:ZBH) ("Zimmer Biomet"). The expiration of the waiting period under the HSR Act represents a significant milestone in the regulatory approval process, satisfying one of the conditions required to complete the proposed merger with Zimmer Biomet. With the HSR Act waiting period expired, the transaction now re

      3/11/25 4:01:00 PM ET
      $FNA
      $ZBH
      Medical/Dental Instruments
      Health Care
      Industrial Specialties
    • Paragon 28 to Feature Several Recent Product Launches at The American Academy of Orthopaedic Surgeons Annual Conference

      Paragon 28, Inc. (NYSE:FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, is pleased to announce its participation in the American Academy of Orthopaedic Surgeons ("AAOS"). From March 10th – 14th, Paragon 28 will feature a suite of recently launched products intended to enhance patient outcomes and the surgeon experience, including: SMART 28℠ Case Management Portal featuring SMART Bun-Yo-Matic℠ Digital case management platform designed to streamline surgical planning and execution, integrating AI, data analytics, and 3D modeling​. Provides an intuitive interface for case scheduling, direct communication with engineers, and conversion o

      3/7/25 4:32:00 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care

    $FNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Paragon 28 Inc.

      SC 13G - Paragon 28, Inc. (0001531978) (Subject)

      8/9/24 9:02:32 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Paragon 28 Inc. (Amendment)

      SC 13G/A - Paragon 28, Inc. (0001531978) (Subject)

      2/14/24 3:29:50 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Paragon 28 Inc. (Amendment)

      SC 13G/A - Paragon 28, Inc. (0001531978) (Subject)

      2/13/24 4:23:50 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care

    $FNA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Dacosta Albert bought $255,226 worth of shares (28,000 units at $9.12) (SEC Form 4)

      4 - Paragon 28, Inc. (0001531978) (Issuer)

      3/18/24 5:34:02 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care
    • Dacosta Albert bought $259,555 worth of shares (30,500 units at $8.51) (SEC Form 4)

      4 - Paragon 28, Inc. (0001531978) (Issuer)

      11/13/23 8:00:07 AM ET
      $FNA
      Medical/Dental Instruments
      Health Care

    $FNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Dacosta Albert returned 11,753,724 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Paragon 28, Inc. (0001531978) (Issuer)

      4/21/25 5:00:07 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care
    • Director Wright Kristina returned 32,118 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Paragon 28, Inc. (0001531978) (Issuer)

      4/21/25 5:00:10 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care
    • Chief Commercial Officer Jarboe Matthew returned 575,320 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Paragon 28, Inc. (0001531978) (Issuer)

      4/21/25 5:00:14 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care

    $FNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Paragon 28 downgraded by Needham

      Needham downgraded Paragon 28 from Buy to Hold

      1/29/25 2:02:26 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care
    • Paragon 28 downgraded by William Blair

      William Blair downgraded Paragon 28 from Outperform to Mkt Perform

      1/29/25 7:36:30 AM ET
      $FNA
      Medical/Dental Instruments
      Health Care
    • William Blair initiated coverage on Paragon 28

      William Blair initiated coverage of Paragon 28 with a rating of Outperform

      9/29/23 7:20:32 AM ET
      $FNA
      Medical/Dental Instruments
      Health Care

    $FNA
    Leadership Updates

    Live Leadership Updates

    See more
    • Paragon 28 Appoints Dave Demski to Board of Directors

      Paragon 28, Inc. (NYSE:FNA), (the "Company") a leader in foot and ankle surgical solutions, today announced the appointment of Dave Demski to serve as an independent director of the Company, effective immediately. Mr. Demski brings a wealth of global orthopedic expertise, with over two decades of executive leadership experience. With the addition of Mr. Demski, the Company increased the size of its Board of Directors from eight members to nine members and has further strengthened its strategic oversight and governance capabilities. Mr. Demski most recently served as the President and CEO of Globus Medical from August 2017 to April 2022, guiding the organization through a period of signifi

      12/11/24 9:00:00 AM ET
      $ATEC
      $FNA
      Medical/Dental Instruments
      Health Care
    • Appointment of Stephen M. Deitsch as new Chief Financial Officer

      OXFORD, United Kingdom, April 04, 2024 (GLOBE NEWSWIRE) -- OrganOx, a medical device company which is changing the paradigm in liver transplantation in the US and Europe with its groundbreaking normothermic machine perfusion technology, today announces that Stephen (Steve) M. Deitsch will be joining OrganOx as Chief Financial Officer ("CFO") on April 8, 2024. Steve joins OrganOx from Paragon 28 (NYSE:FNA), a leading medical device company exclusively focused on the foot and ankle orthopaedic market, where he has held the role of CFO since September 2020. Steve's leadership was instrumental in Paragon 28's successful IPO on the NYSE in the fall of 2021. Prior to Paragon 28, Steve held CFO r

      4/4/24 11:43:23 AM ET
      $FNA
      Medical/Dental Instruments
      Health Care
    • Paragon 28 Announces Appointment of Meghan Scanlon to Board of Directors

      Paragon 28, Inc. (NYSE:FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today the appointment of Meghan Scanlon to its Board of Directors. Ms. Scanlon has joined the Board's Compensation and Quality, Technology and Regulatory Committees. Ms. Scanlon has more than 20 years of senior leadership experience with global medical device companies. She currently serves as senior vice president and president, Urology and Pelvic Health, for Boston Scientific Corporation and is a member of the Boston Scientific Executive Committee. Ms. Scanlon also is a member of the Boston Scientific Global Council for Inclusion, serving as the executive sp

      3/28/22 4:02:00 PM ET
      $FNA
      Medical/Dental Instruments
      Health Care